Business Context and Reporting Period
Aimei Health Technology Co., Ltd. (AFJK), a Cayman Islands-based emerging growth company, filed this Form 8-K on November 26, 2025. The filing reports the results of an Extraordinary General Meeting (EGM) held on the same date to approve critical amendments regarding the company's timeline to consummate an initial business combination and the terms of its trust account.
Key Financial Metrics and Capital Structure
- Redemptions: Holders of 3,942,661 Public Shares exercised redemption rights at approximately $11.37 per share, totaling approximately $44.8 million.
- Trust Account Balance: Following redemptions, the Trust Account balance is approximately $0.7 million.
- Outstanding Shares: Post-redemption, the company has 2,179,072 ordinary shares outstanding.
- Extension Fee Adjustment: The monthly fee to extend the business combination deadline was reduced from a flat $150,000 to the lesser of $80,000 or $0.033 per outstanding Public Share.
Material Changes Versus Prior Period
- Extension of Deadline: The deadline to consummate a business combination was extended from 24 months (December 6, 2025) to 36 months (December 6, 2026) from the IPO date.
- Trust Agreement Amendment: The cost structure for extending the combination period was modified to lower the financial burden on the company for future extensions.
- Auditor Change: MaloneBailey, LLP was appointed as the independent registered public accounting firm for the year ended December 31, 2025.
- Share Count Reduction: Significant reduction in outstanding shares due to the exercise of redemption rights by shareholders.
Guidance, Outlook, and Risks
The filing confirms the company's continued pursuit of an initial business combination, specifically referencing a previously announced "United Hydrogen Business Combination." The extension to December 6, 2026, provides additional time to finalize this transaction. The filing includes standard forward-looking statements disclaiming obligations to update expectations and notes risks related to the ability to complete a business combination. The company explicitly states this report does not constitute an offer to sell securities.
Investor Verification Checklist
- Verify the final closing status of the "United Hydrogen Business Combination" and whether the extended deadline of December 6, 2026, is sufficient.
- Confirm the exact remaining cash balance in the Trust Account ($0.7 million) and its adequacy to cover ongoing operational expenses until a combination is consummated.
- Review the specific terms of the "United Hydrogen" deal to understand the redemption mechanics for the 987,260 shares tendered for the combination but not the EGM.
- Assess the impact of the reduced share count (2.18 million) on the company's ability to meet Nasdaq listing requirements.